← Eichor
Condition: Cutaneous Sarcoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cutaneous Sarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT03889899Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
Phase 2 · 3 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT07007273A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
NA · 1 location(s) · Alpha Tau Medical LTD. · NCT04534127IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
NA · 1 location(s) · Institut Claudius Regaud · NCT06967961A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional
Phase 1/Phase 2 · 11 location(s) · GI Innovation, Inc. · NCT05824975ACTengine® IMA203 Combined With mRNA-4203
Phase 1 · 4 location(s) · Immatics US, Inc. · NCT06946225Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Phase 2 · 1 location(s) · University of California, Irvine · NCT06580002Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
NA · 2 location(s) · Alpha Tau Medical LTD. · NCT04068155
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.